Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia

Reproductive Sciences

Volumn 22, Issue 3, 2015, Pages 329-334

  El Behery, Manal M ^a   Saleh, Hend S ^a   Ibrahiem, Moustafa A ^a   Kamal, Ebtesam M ^a   Kassem, Gamal A ^a   Mohamed, Mohamed El Sayed ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

endometrial hyperplasia; LNG IUS; Mirena; progesterone

Indexed keywords

LEVONORGESTREL; PROGESTERONE; DYDROGESTERONE;

ADULT; AMENORRHEA; ARTICLE; BREAST TENDERNESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIAL THICKNESS; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; MOOD DISORDER; NAUSEA; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; SIDE EFFECT; TABLET; TRANSVAGINAL ECHOGRAPHY; UTERUS BLEEDING; WEIGHT GAIN; ADVERSE EFFECTS; COMPARATIVE STUDY; DRUG EFFECTS; ECHOGRAPHY; EGYPT; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; INTRAUTERINE CONTRACEPTIVE DEVICE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; REMISSION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; DYDROGESTERONE; EGYPT; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PATIENT SATISFACTION; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924798200     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114542014     Document Type: Article

References (21)

1. Lee TS, Seong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006). J Clin Oncol. 2011; 41 (6). 817-819
2. Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009; 63 (1). 39-44
3. Varma R, Soneja H, Bhatia K, et al. The effectiveness of alevonorgestrel releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008; 139 (2). 169-175
4. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas. 2007; 57 (2). 210-213
5. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997; 90 (3). 434-440
6. Wildemeersch D, Dhont M. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol. 2003; 188 (5). 1297-1298
7. Speroff L, D, arney P A Clinical Guide for Contraception. 5 th ed. Philadelphia, PA: Lippincott Williams; 2010. Philadelphia, PA: Lippincott Williams; 2010 :
8. Bahmondes L, Petta CA, Fernandes A, Monterio I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, pelvic pain and dysmenorrhea. Contraception. 2007; 75 (suppl 6). S134-S139
9. Lee SY, Kim MK, Park H, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol. 2010; 21 (2). 102-105
10. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 2006; 125 (2). 259-264
11. Bese T, Vural A, Ozturk M, et al. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer. 2006; 16 (2). 809-813
12. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997; 90 (3). 434-440
13. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res ClinObstetGynaecol. 2001; 15 (3). 393-405
14. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003; 91 (3). 526-533
15. Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010; 203 (6). 547.e1-547.e10
16. Lee SY, Kim MK, Park H, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol. 2010; 21 (2). 102-105
17. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of and oral progestins versus observation only. Gynecol Oncol. 2008; 111 (1). 68-73
18. Reed SD, Voigt LF, Newton KM, et al. Progestin therapy of complex endometrial hyperplasi with and without atypia. Obstet Gynecol. 2009; 113 (3). 655-652
19. Loose DS, Stancel GM. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 2006 ). Estrogens and progestins. In: BruntonLLLazoJSParkerKL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 1541-1571. Brunton LL Lazo JS Parker KL, ed. New York, NY: McGraw-Hill; 2006: 1541-1571.
20. Nick P, Haitham H, Roopen A, Michael S. The 2013 British menopause society & women's health concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19 (2). 59-68
21. Demirkiran F, Yavuz E, Erenel H, Bese T, Arvas M, Sanioglu C. Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage(D&C). Arch Gynecol Obstet. 2012; 286 (5). 1277-1282